Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (31-40 of 204) with videos related to

Pageof 21
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis DrugsTawanda Gumbo, Jan-Willem C Alffenaar
Biorxiv : the Preprint Server for Biology|August 6, 2025
Tigecycline pharmacodynamics in the hollow fiber system of <i>Mycobacterium avium</i>-complex lung disease, and the utility of MICs and time-kill studies in drug developmentDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|September 14, 2012
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolatesJotam Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
The Journal of Infectious Diseases|February 5, 2015
Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant TuberculosisJotam Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Plos One|April 4, 2020
Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosisShashikant Srivastava, Moti Chapagain, Tawanda Gumbo
The European Respiratory Journal|July 2, 2013
In vitro susceptibility testing and totally drug-resistant tuberculosisShashikant Srivastava, Carleton Sherman, Tawanda Gumbo
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistanceShashikant Srivastava, Devyani Deshpande, Tawanda Gumbo
The Pediatric Infectious Disease Journal|November 1, 2014
Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosisJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Cardiovascular Ultrasound|July 31, 2012
Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept studyMpiko Ntsekhe, Bongani M Mayosi, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2012
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapyJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Pageof 21

Showing results (31-40 of 204) with videos related to

Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis DrugsTawanda Gumbo, Jan-Willem C Alffenaar
Biorxiv : the Preprint Server for Biology|August 6, 2025
Tigecycline pharmacodynamics in the hollow fiber system of <i>Mycobacterium avium</i>-complex lung disease, and the utility of MICs and time-kill studies in drug developmentDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Antimicrobial Agents and Chemotherapy|September 14, 2012
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolatesJotam Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
The Journal of Infectious Diseases|February 5, 2015
Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant TuberculosisJotam Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Plos One|April 4, 2020
Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosisShashikant Srivastava, Moti Chapagain, Tawanda Gumbo
The European Respiratory Journal|July 2, 2013
In vitro susceptibility testing and totally drug-resistant tuberculosisShashikant Srivastava, Carleton Sherman, Tawanda Gumbo
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistanceShashikant Srivastava, Devyani Deshpande, Tawanda Gumbo
The Pediatric Infectious Disease Journal|November 1, 2014
Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosisJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Cardiovascular Ultrasound|July 31, 2012
Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept studyMpiko Ntsekhe, Bongani M Mayosi, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2012
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapyJotam G Pasipanodya, Shashikant Srivastava, Tawanda Gumbo
Pageof 21